3:28 PM
Nov 27, 2013
 |  BC Extra  |  Top Story

Myriad notifies Crescendo of acquisition interest

Myriad Genetics Inc. (NASDAQ:MYGN) disclosed in an SEC filing that it provided notice of its preliminary interest in exercising an option to acquire molecular diagnostics company Crescendo Bioscience Inc. (South San Francisco, Calif.)....

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >